PHD 2.0 Analytic Data Dictionaries Contents All Payer’S Claims Data (APCD) – Dental

Total Page:16

File Type:pdf, Size:1020Kb

PHD 2.0 Analytic Data Dictionaries Contents All Payer’S Claims Data (APCD) – Dental PHD 2.0 Analytic Data Dictionaries Contents All Payer’s Claims Data (APCD) – Dental ....................................................................................................... 3 All Payer’s Claims Data (APCD) MassHealth Member Eligibility ................................................................. 29 All Payer’s Claims Data (APCD) – Medical ................................................................................................... 35 All Payer’s Claims Data (APCD) – Pharmacy ................................................................................................ 79 All Payer’s Claims Data (APCD) -Product ................................................................................................... 112 All Payers Claims Database (APCD) – Provider ......................................................................................... 120 Birth Records Infant/Child: Registry of Vital Records and Statistics ......................................................... 145 Birth Records MOM: Registry of Vital Records and Statistics ................................................................... 155 Bureau of Substance Addiction Services (BSAS) ....................................................................................... 171 Casemix Emergency Department Diagnostic (PHDCM.ED_DIAG) Result ................................................. 188 Casemix Emergency Department (PHDCM.ED) Visit ................................................................................ 189 Casemix ED_ORG (PHDCM.ED_ORG) ........................................................................................................ 194 Casemix Emergency Department Procedure (PHDCM.ED_PROC) ........................................................... 195 Casemix Inpatient Hospital Discharge Diagnosis (PHDCM.HD_DIAG) ..................................................... 200 Casemix Inpatient Hospital Discharge (PHDCM.HD_HD) .......................................................................... 201 Casemix Inpatient Hospital Discharge Procedure Table (PHDCM.HD_ORG) ............................................ 206 Casemix - Inpatient Hospital Discharge Procedure (PHDCM.HD_PROC) ................................................. 207 Casemix - Hospital Outpatient Observation (PHDCM.OO) Visit ............................................................... 208 Census ....................................................................................................................................................... 215 1. POP_TOWNTOTAL: Total population by city/town 2011 to 2019 ............................................ 215 2. POP_TOWN_11AGE: Total Population by 11 age groups by city/town 2011-2019 ................. 215 3. POP_TOWN_19AGE: Total Population by 19 age groups by city/town 2011-2019 ................. 215 4. female_towncity_18age_race: 2019 Total Female Population by 18 age groups and race/ethnicity by city/town .............................................................................................................. 215 5. POP_STATETOTAL: Statewide Total Population by gender and race/ethnicity 2011-2019 ..... 215 6. POP_STATE_11AGE: .................................................................................................................. 215 6. POP_STATE_19AGE: .................................................................................................................. 215 7. POP_ACS_ZCTA: ........................................................................................................................ 215 8. POP_ACS_COUNTY: Dataset downloaded from The Public Health Disparities Geocoding Project https://www.hsph.harvard.edu/thegeocodingproject/ ................................................................... 215 9. POP_ACS_TOWN: Data by city and town from the 2014-2018 American Community Survey 5- Year 215 Death Records - Registry of Vital Records and Statistics Mortality .......................................................... 229 Family Homelessness - Department of Housing and Community Development (DHCD) ......................... 236 Department of Industrial Accidents (DIA) - Worker’s Compensation ...................................................... 240 Department of Corrections (DOC) ............................................................................................................ 247 Department of Mental Health (DMH) ....................................................................................................... 252 SNAP Benefit Program - Department of Transitional Assistance (DTA) ................................................... 287 1 Special Analytic Projects, Office of Population Health updated: July 19, 2021 Veteran’s Benefits - Department of Veterans’ Services (DVS) ................................................................. 293 Early Intervention Clients (EI_CLIENTS) .................................................................................................... 296 Early Intervention (EI) Discharge .............................................................................................................. 300 Early Intervention Evaluation (EI_Evaluation) .......................................................................................... 307 Early Intervention Diagnosis Reference .................................................................................................... 312 Fetal Deaths - Registry of Vital Records and Statistics .............................................................................. 313 House of Correction (HOC) ....................................................................................................................... 325 OEND_Enrollments ................................................................................................................................... 327 OEND_Refills ............................................................................................................................................. 329 OEND Rescues ........................................................................................................................................... 331 OEND_RescuesbyLocation ........................................................................................................................ 334 OEND_RescuesbyTown ............................................................................................................................. 336 Massachusetts Ambulance Trip Record Information System (MATRIS) ................................................... 338 Hepatitis A – MAVEN ................................................................................................................................ 358 Hepatitis C - MAVEN ................................................................................................................................. 360 HIV_Incidence ........................................................................................................................................... 362 HIV Prevalence .......................................................................................................................................... 364 Massachusetts Cancer Registry (MCR) ..................................................................................................... 368 Prescription Monitoring Program – PMP .................................................................................................. 373 Prescription Monitoring Program Role Spec (PMP_RS) ............................................................................ 382 Postmortem Toxicology (TOX) Results ...................................................................................................... 383 Women, Infants, and Children (WIC) Program - Infant/Child ................................................................... 385 Women, Infants, and Children (WIC) Program - Mom ............................................................................. 395 WIC Supplemental Tables ......................................................................................................................... 401 Appendix 1: APCD Files Linkage Table ...................................................................................................... 404 2 Special Analytic Projects, Office of Population Health updated: July 19, 2021 All Payer’s Claims Data (APCD) - Dental Analytic Data Dictionary (PHDAPCD.DENTAL_14_18) All Payer’s Claims Data (APCD) – Dental ***For details on how to link PHDAPCD.DENTAL with other PHD APCD datasets, please see Appendix 1 in the PHD_Key Facts for working with the data documentation. *** Variable Variable Name Meta Data Format Description ID PHD ID 9 character alphanumeric ID Char Member age at Age in years, ages greater than 89 set to DENT_AGE Num service 999 DENT_CDT HCPCS/CDT Code 5-character CDT code Char 0=services rendered in conjunction with other services on the claim. Negative amounts mean there could have Amount of provider been involved cost sharing where the DENT_CHARGED charges for the claim Num patient paid an amount which rendered line the dollar amount owed by the carrier negative, or the carrier’s internal audit discovered that payment exceeded the contractually allowable benefit or that the carrier had made a duplicate payment. 0= This value is as is submitted by the insurance carrier (with unknown translation) 1=Processed as primary 2=Processed as secondary 3=Processed as tertiary 4=Denied
Recommended publications
  • JOURNAL of VIROLOGY Volume 18 Contents for May Number 2
    JOURNAL OF VIROLOGY Volume 18 Contents for May Number 2 Animal Viruses Isolation and Properties of the Replicase of Encephalomyocarditis Virus. A. TRAUB,* B. DISKIN, H. ROSENBERG, AND E. KALMAR ...... ............... 375 Synthesis and Integration of Viral DNA in Chicken Cells at Different Times After Infection with Various Multiplicities of Avian Oncornavirus. ALLAN T. KHOURY* AND HIDESABURO HANAFUSA ........ .......................... 383 RNA Metabolism of Murine Leukemia Virus. III. Identification and Quantitation of Endogenous Virus-Specific mRNA in the Uninfected BALB/c Cell Line JLS-V9. HUNG FAN AND NIKOLAUS MUELLER-LANTZSCH* ..... ............ 401 Endogenous Ecotropic Mouse Type C Viruses Deficient in Replication and Produc- tion of XC Plaques. ULF W RAPP AND ROBERT C. NoWINSKI* ..... ....... 411 Further Characterization of the Friend Murine Leukemia Virus Reverse Tran- scriptase-RNase H Complex. KARIN MOELLING ...... ................... 418 State of the Viral DNA in Rat Cells Transformed by Polyoma Virus. I. Virus Res- cue and the Presence of Nonintegrated Viral DNA Molecules. ISHWARI PRASAD, DIMITRIS ZOUZIAS, AND CLAUDIO BASIUCO* ...... ................ 436 Inhibition of Infectious Rous Sarcoma Virus Production by a Rifamycin Deriva- tive. CHARLES SZABO,* MINA J. BISSELL, AND MELVIN CALVIN ..... ...... 445 Synthesis ofthe Adenovirus-Coded DNA Binding Protein in Infected Cells. ZVEE GILEAD,* KINJI SUGUWARA, G. SHANMUGAM, AND MAURICE GREEN ....... 454 Intracellular Distribution and Sedimentation Properties of Virus-Specific RNA in Two Clones of BHK Cells Transformed by Polyoma Virus. IAN H. MAX- WELL .............................................................. 461 Inherited Resistance to N- and B-Tropic Murine Leukemia Viruses In Vitro: Titration Patterns in Strains SIM and SIM.R Congenic at the Fv-1 Locus. VERA SCHUH, MARTIN E. BLACKSTEIN, AND ARTHUR A.
    [Show full text]
  • TNF Decoy Receptors Encoded by Poxviruses
    pathogens Review TNF Decoy Receptors Encoded by Poxviruses Francisco Javier Alvarez-de Miranda † , Isabel Alonso-Sánchez † , Antonio Alcamí and Bruno Hernaez * Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas, Campus de Cantoblanco, Universidad Autónoma de Madrid, Nicolás Cabrera 1, 28049 Madrid, Spain; [email protected] (F.J.A.-d.M.); [email protected] (I.A.-S.); [email protected] (A.A.) * Correspondence: [email protected]; Tel.: +34-911-196-4590 † These authors contributed equally. Abstract: Tumour necrosis factor (TNF) is an inflammatory cytokine produced in response to viral infections that promotes the recruitment and activation of leukocytes to sites of infection. This TNF- based host response is essential to limit virus spreading, thus poxviruses have evolutionarily adopted diverse molecular mechanisms to counteract TNF antiviral action. These include the expression of poxvirus-encoded soluble receptors or proteins able to bind and neutralize TNF and other members of the TNF ligand superfamily, acting as decoy receptors. This article reviews in detail the various TNF decoy receptors identified to date in the genomes from different poxvirus species, with a special focus on their impact on poxvirus pathogenesis and their potential use as therapeutic molecules. Keywords: poxvirus; immune evasion; tumour necrosis factor; tumour necrosis factor receptors; lymphotoxin; inflammation; cytokines; secreted decoy receptors; vaccinia virus; ectromelia virus; cowpox virus Citation: Alvarez-de Miranda, F.J.; Alonso-Sánchez, I.; Alcamí, A.; 1. TNF Biology Hernaez, B. TNF Decoy Receptors TNF is a potent pro-inflammatory cytokine with a broad range of biological effects, Encoded by Poxviruses. Pathogens ranging from the activation of inflammatory gene programs to cell differentiation or 2021, 10, 1065.
    [Show full text]
  • ICD-9 Diagnosis Codes Effective 10/1/2011 (V29.0) Source: Centers for Medicare and Medicaid Services
    ICD-9 Diagnosis Codes effective 10/1/2011 (v29.0) Source: Centers for Medicare and Medicaid Services 0010 Cholera d/t vib cholerae 00801 Int inf e coli entrpath 01086 Prim prg TB NEC-oth test 0011 Cholera d/t vib el tor 00802 Int inf e coli entrtoxgn 01090 Primary TB NOS-unspec 0019 Cholera NOS 00803 Int inf e coli entrnvsv 01091 Primary TB NOS-no exam 0020 Typhoid fever 00804 Int inf e coli entrhmrg 01092 Primary TB NOS-exam unkn 0021 Paratyphoid fever a 00809 Int inf e coli spcf NEC 01093 Primary TB NOS-micro dx 0022 Paratyphoid fever b 0081 Arizona enteritis 01094 Primary TB NOS-cult dx 0023 Paratyphoid fever c 0082 Aerobacter enteritis 01095 Primary TB NOS-histo dx 0029 Paratyphoid fever NOS 0083 Proteus enteritis 01096 Primary TB NOS-oth test 0030 Salmonella enteritis 00841 Staphylococc enteritis 01100 TB lung infiltr-unspec 0031 Salmonella septicemia 00842 Pseudomonas enteritis 01101 TB lung infiltr-no exam 00320 Local salmonella inf NOS 00843 Int infec campylobacter 01102 TB lung infiltr-exm unkn 00321 Salmonella meningitis 00844 Int inf yrsnia entrcltca 01103 TB lung infiltr-micro dx 00322 Salmonella pneumonia 00845 Int inf clstrdium dfcile 01104 TB lung infiltr-cult dx 00323 Salmonella arthritis 00846 Intes infec oth anerobes 01105 TB lung infiltr-histo dx 00324 Salmonella osteomyelitis 00847 Int inf oth grm neg bctr 01106 TB lung infiltr-oth test 00329 Local salmonella inf NEC 00849 Bacterial enteritis NEC 01110 TB lung nodular-unspec 0038 Salmonella infection NEC 0085 Bacterial enteritis NOS 01111 TB lung nodular-no exam 0039
    [Show full text]
  • Escherichia Coli Saccharomyces Cerevisiae Bacillus Subtilis はB
    研究開発等に係る遺伝子組換え生物等の第二種使用等に当たって執るべき拡散防止措 置等を定める省令の規定に基づき認定宿主ベクター系等を定める件 (平成十六年一月二十九日文部科学省告示第七号) 最終改正:令和三年二月十五日文部科学省告示第十三号 (認定宿主ベクター系) 第一条 研究開発等に係る遺伝子組換え生物等の第二種使用等に当たって執るべき拡散防止 措置等を定める省令(以下「省令」という。)第二条第十三号の文部科学大臣が定める認 定宿主ベクター系は、別表第一に掲げるとおりとする。 (実験分類の区分ごとの微生物等) 第二条 省令第三条の表第一号から第四号までの文部科学大臣が定める微生物等は、別表第 二の上欄に掲げる区分について、それぞれ同表の下欄に掲げるとおりとする。 (特定認定宿主ベクター系) 第三条 省令第五条第一号ロの文部科学大臣が定める特定認定宿主ベクター系は、別表第一 の2の項に掲げる認定宿主ベクター系とする。 (自立的な増殖力及び感染力を保持したウイルス及びウイロイド) 第四条 省令別表第一第一号ヘの文部科学大臣が定めるウイルス及びウイロイドは、別表第 三に掲げるとおりとする。 別表第1(第1条関係) 区 分 名 称 宿主及びベクターの組合せ 1 B1 (1) EK1 Escherichia coli K12株、B株、C株及びW株又は これら各株の誘導体を宿主とし、プラスミド又は バクテリオファージの核酸であって、接合等によ り宿主以外の細菌に伝達されないものをベクター とするもの(次項(1)のEK2に該当するものを除 く。) (2) SC1 Saccharomyces cerevisiae又はこれと交雑可能な 分類学上の種に属する酵母を宿主とし、これらの 宿主のプラスミド、ミニクロモソーム又はこれら の誘導体をベクターとするもの(次項(2)のSC2 に該当するものを除く。) (3) BS1 Bacillus subtilis Marburg168株、この誘導体又 はB. licheniformis全株のうち、アミノ酸若しく は核酸塩基に対する複数の栄養要求性突然変異を 有する株又は胞子を形成しない株を宿主とし、こ れらの宿主のプラスミド(接合による伝達性のな いものに限る。)又はバクテリオファージの核酸 をベクターとするもの(次項(3)のBS2に該当す るものを除く。) (4) Thermus属細菌 Thermus属細菌(T. thermophilus、T. aquaticus、 T. flavus、T. caldophilus及びT. ruberに限る。) を宿主とし、これらの宿主のプラスミド又はこの 誘導体をベクターとするもの (5) Rhizobium属細菌 Rhizobium属細菌(R. radiobacter(別名Agroba- cterium tumefaciens)及びR. rhizogenes(別名 Agrobacterium rhizogenes)に限る。)を宿主と し、これらの宿主のプラスミド又はRK2系のプラ スミドをベクターとするもの (6) Pseudomonas putida Pseudomonas putida KT2440株又はこの誘導体を 宿主とし、これら宿主への依存性が高く、宿主以 外の細胞に伝達されないものをベクターとするも の (7) Streptomyces属細菌 Streptomyces属細菌(S. avermitilis、S. coel- icolor [S. violaceoruberとして分類されるS. coelicolor A3(2)株を含む]、S. lividans、S. p- arvulus、S. griseus及びS.
    [Show full text]
  • List of Codes Used to Identify Measures Reported in the QDFC
    List of Codes Used to Identify Measures Reported in the Quarterly Dialysis Facility Compare Reports July 2018 List of Codes Used to Identify Measures Reported in the Quarterly Dialysis Facility Compare Reports Table of Contents Table 1a: Transfusion Summary for Medicare Dialysis Patients, Codes Used for Exclusions 3 CARCINOMA 3 COAGULATION 5 HEAD/NECK CANCER 5 HEMOLYTIC OR APLASTIC ANEMIA 9 LEUKEMIA 11 LYMPHOMA 15 METASTATIC 27 MYELOMA, ETC. 29 OTHER CANCER 30 SICKLE CELL 34 SOLID ORGAN CANCER 34 Table 1b: Transfusion Summary for Medicare Dialysis Patients, Codes Used to Identify Transfusion Events .................................................................................................................. 45 REVENUE CENTER CODES 45 PROCEDURE CODES 45 VALUE CODES 46 HCPCS CODE 46 Table 2a: Vascular Access Measures (SFR and Long-Term Catheter) for Medicare Dialysis Patients Based on Medicare Claims, Codes Used for Exclusions ........................................... 46 Produced by The University of Michigan Kidney Epidemiology and Cost Center Page 1 of 135 List of Codes Used to Identify Measures Reported in the Quarterly Dialysis Facility Compare Reports July 2018 COMA 46 END STAGE LIVER DISEASE 48 METASTATIC CANCER 48 Table 2b: Standardized Fistulae Rate (SFR) for Medicare Dialysis Patients Based on Medicare Claims, Codes Used for Prevalent Comorbidities Adjusted in Model .................................... 50 ANEMIA 50 CORONARY ARTERY DISEASE 52 CONGESTIVE HEART FAILURE 55 CEREBROVASCULAR DISEASE 56 CHRONIC OBSTRUCTIVE PULMONARY DISEASE 68 DIABETES 69 DRUG DEPENDENCE 79 INFECTIONS (NON-VASCULAR ACCESS-RELATED): 93 PERIPHERAL VASCULAR DISEASE (INCLUDES ARTERIAL, VENOUS AND NONSPECIFIC DISEASES) 124 Table 3: Dialysis Adequacy ...................................................................................................
    [Show full text]
  • Client Services Manual Public Health Laboratory
    CLIENT SERVICES MANUAL PUBLIC HEALTH LABORATORY COUNTY OF SANTA CLARA 2220 MOORPARK AVE, 2ND FLOOR SAN JOSE, CA 95128 (P) 408.885.4272 | (F) 408.885.4275 http://www.sccgov.org/sites /sccphd/en-us/HealthProviders/Lab Patricia Dadone, Public Health Laboratory Director Sara H. Cody, MD, Health Officer and Public Health Director Table of Contents 1 GENERAL INFORMATION ............................................................................................... 1.1 ROLE .............................................................................................................................................................. 1.1 MISSION STATEMENT ..................................................................................................................................... 1.1 ABBREVIATIONS.............................................................................................................................................. 1.2 LABORATORY CERTIFICATIONS ........................................................................................................................ 1.4 CLIENT SERVICES ............................................................................................................................................ 1.5 Hours of Operation: .............................................................................................................................. 1.5 Supplies ..................................................................................................................................................
    [Show full text]
  • Specimen Type, Collection Methods, and Diagnostic Assays Available For
    Specimen type, collection methods, and diagnostic assays available for the detection of poxviruses from human specimens by the Poxvirus and Rabies Branch, Centers for Disease Control and Prevention1. Specimen Orthopoxvirus Parapoxvirus Yatapoxvirus Molluscipoxvirus Specimen type collection method PCR6 Culture EM8 IHC9,10 Serology11 PCR12 EM8 IHC9,10 PCR13 EM8 PCR EM8 Lesion material Fresh or frozen Swab 5 Lesion material [dry or in media ] [vesicle / pustule Formalin fixed skin, scab / crust, etc.] Paraffin block Fixed slide(s) Container Lesion fluid Swab [vesicle / pustule [dry or in media5] fluid, etc.] Touch prep slide Blood EDTA2 EDTA tube 7 Spun or aliquoted Serum before shipment Spun or aliquoted Plasma before shipment CSF3,4 Sterile 1. The detection of poxviruses by electron microscopy (EM) and immunohistochemical staining (IHC) is performed by the Infectious Disease Pathology Branch of the CDC. 2. EDTA — Ethylenediaminetetraacetic acid. 3. CSF — Cerebrospinal fluid. 4. In order to accurately interpret test results generated from CSF specimens, paired serum must also be submitted. 5. If media is used to store and transport specimens a minimal amount should be used to ensure as little dilution of DNA as possible. 6. Orthopoxvirus generic real-time polymerase chain reaction (PCR) assays will amplify DNA from numerous species of virus within the Orthopoxvirus genus. Species-specific real-time PCR assays are available for selective detection of DNA from variola virus, vaccinia virus, monkeypox virus, and cowpox virus. 7. Blood is not ideal for the detection of orthopoxviruses by PCR as the period of viremia has often passed before sampling occurs. 8. EM can reveal the presence of a poxvirus in clinical specimens or from virus culture, but this technique cannot differentiate between virus species within the same genus.
    [Show full text]
  • Herpes Simplex Infections in Atopic Eczema
    Arch Dis Child: first published as 10.1136/adc.60.4.338 on 1 April 1985. Downloaded from Archives of Disease in Childhood, 1985, 60, 338-343 Herpes simplex infections in atopic eczema T J DAVID AND M LONGSON Department of Child Health and Department of Virology University of Manchester SUMMARY One hundred and seventy nine children with atopic eczema were studied prospec- tively for two and three quarter years; the mean period of observation being 18 months. Ten children had initial infections with herpes simplex. Four children, very ill with a persistently high fever despite intravenous antibiotics and rectal aspirin, continued to produce vesicles and were given intravenous acyclovir. There were 11 recurrences among five patients. In two patients the recurrences were as severe as the initial lesions, and one of these children had IgG2 deficiency. Use of topical corticosteroids preceded the episode of herpes in only three of the 21 episodes. Symptomatic herpes simplex infections are common in children with atopic eczema, and are suggested by the presence of vesicles or by infected eczema which does not respond to antibiotic treatment. Virological investigations are simple and rapid: electron microscopy takes minutes, and cultures are often positive within 24 hours. Patients with atopic eczema are susceptible to features, and treatment of herpes simplex infections copyright. particularly severe infections with herpes simplex in a group of 179 children with atopic eczema. virus. Most cases are probably due to type 1,1 but eczema herpeticum due to the type 2 virus has been Patients and methods described,2 and the incidence of type 2 infections may be underestimated because typing is not usually Between January 1982 and September 1984 all performed.
    [Show full text]
  • Herpes: a Patient's Guide
    Herpes: A Patient’s Guide Herpes: A Patient’s Guide Introduction Herpes is a very common infection that is passed through HSV-1 and HSV-2: what’s in a name? ....................................................................3 skin-to-skin contact. Canadian studies have estimated that up to 89% of Canadians have been exposed to herpes simplex Herpes symptoms .........................................................................................................4 type 1 (HSV-1), which usually shows up as cold sores on the Herpes transmission: how do you get herpes? ................................................6 mouth. In a British Columbia study, about 15% of people tested positive for herpes simplex type 2 (HSV-2), which Herpes testing: when is it useful? ..........................................................................8 is the type of herpes most commonly thought of as genital herpes. Recently, HSV-1 has been showing up more and Herpes treatment: managing your symptoms ...................................................10 more on the genitals. Some people can have both types of What does herpes mean to you: receiving a new diagnosis ......................12 herpes. Most people have such minor symptoms that they don’t even know they have herpes. What does herpes mean to you: accepting your diagnosis ........................14 While herpes is very common, it also carries a lot of stigma. What does herpes mean to you: dating with herpes ....................................16 This stigma can lead to anxiety, fear and misinformation
    [Show full text]
  • Symptoms and Signs of Herpes Simplex Virus What to Do—HERPES! Provider’S Guide for Uncommon Suspected Sexual Abuse Scenarios Ann S
    Symptoms and Signs of Herpes Simplex Virus What to Do—HERPES! Provider’s Guide for Uncommon Suspected Sexual Abuse Scenarios Ann S. Botash, MD Background Herpes can present in any of several ways: • herpetic gingivostomatitis • herpetic whitlow, • herpes labialis • herpes gladiotorum • genital herpes • herpes encephalitis • herpetic keratoconjuctivitis • eczema herpeticum The differential diagnosis of ulcerative lesions in the genital area is broad. Infectious causes: • chancroid • syphilis, • genital HSV infection • scabies, • granuloma inguinale (donovanosis) • CMV or EBV • candida, • varicella or herpes zoster virus (VZV) • lymphogranuloma venereum Non-infectious causes: • lichen planus • Behçet syndrome • trauma History Symptoms Skin lesions are typically preceded by prodromal symptoms: • burning and paresthesia at the •malaise site •myalgia • lymphadenopathy •loss of appetite • fever •headaches Exposure history Identify anyone with any of the various presentations of genital or extra- genital ulcers. Determine if there has been a recurrence. Determine if there are any risk factors for infection: • eczematous skin conditions • immunocompromised state of patient and/or alleged perpetrator. Rule out autoinoculation or consensual transmission. Physical Cutaneous lesions consist of small, monomorphous vesicles on an erythematous base that rupture into painful, shallow, gray erosions or ulcerations with or without crusting. Clinical diagnosis of genital herpes is not very sensitive or specific. Obtain laboratory cultures for a definitive diagnosis. Lab Tests Viral culture (gold standard)—preferred test • Must be from active lesions. • Vigorously swab unroofed lesion and inoculate into a prepared cell culture. Antigen detection • Order typing of genital lesions in children. • DFA distinguishes between HSV1 & 2, EIA does not. Cytologic detection • Tzanck Prep is insensitive (50%) and non-specific. • PCR testing is sensitive and specific but the role in the diagnosis of genital ulcers is unclear.
    [Show full text]
  • What Is Herpes?
    #35 HERPES PATIENT PERSPECTIVES What is herpes? Herpes is a viral skin infection caused by the herpes simplex virus (HSV). HSV infections are very common and have different names depending upon the location on the body that is affected. Herpes most commonly affects the lips and mouth orolabial( herpes or “cold sores”), as well as genitalia (genital herpes). It can also affect fingertipsherpetic ( whitlow). In patients with active eczema, open areas can get infected with HSV (eczema herpeticum). HOW DO PEOPLE GET HERPES? Herpes is very contagious and spreads by direct contact with the affected skin or mucosa of a person who has HSV. HSV is most easily spread when someone has visible lesions affecting the mouth, genitals, or other skin sites. Occasionally, herpes can spread even if there are no visible sores, and it may also live on surfaces contaminated with infected saliva or skin. Once HSV infects a person, the virus remains inactive in the surrounding nerves of that person. This inactive virus can reactivate and cause recurrent outbreaks in the same area that was initially infected. Stress, dehydration, sunburns, and being sick are all triggers for an outbreak. WHAT DOES HERPES LOOK LIKE ON THE SKIN AND WHAT ARE THE SYMPTOMS? Herpes looks like a cluster of tiny fluid-filled blisters that last anywhere between 4-10 days. It may leave a sore behind that takes longer to resolve. Symptoms related to herpes are different for each person. Some patients have painful outbreaks with many sores. Others only have mild symptoms that may go unnoticed. During the first outbreak (or primary infection), there may be fever, chills, muscle aches, and swollen nodes before the herpes lesions appear.
    [Show full text]
  • ICTV Code Assigned: 2011.001Ag Officers)
    This form should be used for all taxonomic proposals. Please complete all those modules that are applicable (and then delete the unwanted sections). For guidance, see the notes written in blue and the separate document “Help with completing a taxonomic proposal” Please try to keep related proposals within a single document; you can copy the modules to create more than one genus within a new family, for example. MODULE 1: TITLE, AUTHORS, etc (to be completed by ICTV Code assigned: 2011.001aG officers) Short title: Change existing virus species names to non-Latinized binomials (e.g. 6 new species in the genus Zetavirus) Modules attached 1 2 3 4 5 (modules 1 and 9 are required) 6 7 8 9 Author(s) with e-mail address(es) of the proposer: Van Regenmortel Marc, [email protected] Burke Donald, [email protected] Calisher Charles, [email protected] Dietzgen Ralf, [email protected] Fauquet Claude, [email protected] Ghabrial Said, [email protected] Jahrling Peter, [email protected] Johnson Karl, [email protected] Holbrook Michael, [email protected] Horzinek Marian, [email protected] Keil Guenther, [email protected] Kuhn Jens, [email protected] Mahy Brian, [email protected] Martelli Giovanni, [email protected] Pringle Craig, [email protected] Rybicki Ed, [email protected] Skern Tim, [email protected] Tesh Robert, [email protected] Wahl-Jensen Victoria, [email protected] Walker Peter, [email protected] Weaver Scott, [email protected] List the ICTV study group(s) that have seen this proposal: A list of study groups and contacts is provided at http://www.ictvonline.org/subcommittees.asp .
    [Show full text]